Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. The minutes of each evaluation committee meeting, which include the names of ...

Tebentafusp (Kimmtrak, Immunocore) is indicated 'as monotherapy for the treatment of human leukocyte antigen (HLA)‑A*02:01-positive adult patients with unresectable or metastatic uveal melanoma'. The ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this ...

Tebentafusp is recommended, within its marketing authorisation, for treating HLA‑A*02:01-positive unresectable or metastatic uveal melanoma in adults. Tebentafusp is only recommended if the company ...

The Department of Health has asked NICE to produce guidance on using the above technology in the NHS in England. The company has informed NICE that it will not provide an evidence submission for this ...

Interstitial cystitis, also known as bladder pain syndrome, is a chronic inflammatory condition of the bladder. The main symptoms are pelvic pain, urinary urgency, urinary frequency and nocturia.